Cancers,
Год журнала:
2023,
Номер
15(19), С. 4818 - 4818
Опубликована: Сен. 30, 2023
Using
an
LL2
cell-based
syngeneic
mouse
LC
model,
taxifolin
suppressed
allografts
along
with
the
appearance
of
578
differentially
expressed
genes
(DEGs).
These
DEGs
were
associated
enhancement
processes
related
to
extracellular
matrix
and
lymphocyte
chemotaxis
as
well
reduction
in
pathways
relevant
cell
proliferation.
From
these
DEGs,
we
formulated
12-gene
(TxflSig)
7-gene
(TxflSig1)
panels;
both
predicted
response
ICB
(immune
checkpoint
blockade)
therapy
more
effectively
non-small-cell
lung
cancer
(NSCLC)
than
numerous
well-established
biomarkers,
including
PD-L1.
In
panels,
counterparts
ITGAL,
ITGAX,
TMEM119
downregulated
by
taxifolin.
They
strongly
immune
suppression
LC,
evidenced
their
robust
correlations
major
immunosuppressive
types
(MDSC,
Treg,
macrophage)
multiple
checkpoints
NSCLC
across
human
types.
IIT
(ITGAL-ITGAX-TMEM119)
NSCLC’s
therapy;
stratified
mortality
risk
NSCLC.
The
stromal
expressions
ITGAL
together
tumor
expression
NSCLC,
demonstrated.
Collectively,
report
novel
biomarkers—TxflSig,
TxflSig1,
IIT,
ITGAX—and
taxifolin-derived
attenuation
activities
suggesting
inclusion
therapies
for
Theranostics,
Год журнала:
2024,
Номер
14(5), С. 2127 - 2150
Опубликована: Янв. 1, 2024
Immune
checkpoint
inhibitors
targeting
the
programmed
cell
death
(PD)-1/PD-L1
pathway
have
promise
in
patients
with
advanced
melanoma.
However,
drug
resistance
usually
results
limited
patient
benefits.
Recent
single-cell
RNA
sequencing
studies
elucidated
that
MM
display
distinctive
transcriptional
features
of
tumor
cells,
immune
cells
and
interstitial
including
loss
antigen
presentation
function
exhaustion
CD8+T
extracellular
matrix
secreted
by
fibroblasts
to
prevents
infiltration,
which
leads
a
poor
response
(ICIs).
subgroups
beneficial
anti-tumor
immunity
model
developed
them
remain
be
further
identified.
Cancer Letters,
Год журнала:
2024,
Номер
590, С. 216866 - 216866
Опубликована: Апрель 6, 2024
Bone
metastasis
is
a
common
complication
of
certain
cancers
such
as
melanoma.
The
spreading
cancer
cells
into
the
bone
supported
by
changes
in
marrow
environment.
specific
role
osteocytes
this
process
yet
to
be
defined.
By
RNA-seq
and
chemokines
screening
we
show
that
release
chemokine
CXCL5
when
they
are
exposed
melanoma
cells.
Osteocytes-mediated
secretion
enhanced
migratory
invasive
behaviour
When
expression
receptor,
CXCR2,
was
down-regulated
vitro,
observed
significant
decrease
cell
migration
response
osteocytes.
Furthermore,
with
CXCR2
showed
less
loss
model
vivo.
simultaneously
down-regulating
cells,
progression
abrogated
In
summary,
these
data
suggest
melanoma,
which
mediated
through
CXCL5-CXCR2
pathway.
Abstract
Background
Melanoma
proliferation
is
partly
attributed
to
dysregulated
lipid
metabolism.
The
effectiveness
of
lipid-lowering
drugs
in
combating
cutaneous
melanoma
(CM)
a
subject
ongoing
debate
both
vitro
and
clinical
studies.
Method
This
study
aims
evaluate
the
causal
relationship
between
various
drug
targets,
namely
3-hydroxy-3-methylglutaryl-coenzyme
A
reductase
(HMGCR,
targeted
by
statins),
Proprotein
convertase
subtilisin/kexin
type
9
(PCSK9,
alirocumab
evolocumab),
Niemann-Pick
C1-like
1
(NPC1L1,
ezetimibe),
outcomes
melanoma.
To
mimic
effects
drugs,
we
utilized
two
genetic
tools:
analysis
polymorphisms
affecting
expression
levels
target
genes,
variations
linked
low-density
lipoprotein
cholesterol
genes.
These
were
sourced
from
genome-wide
association
studies
(GWAS).
We
applied
Summary-data-based
Mendelian
Randomization
(SMR)
Inverse
Variance
Weighted
(IVW-MR)
gauge
these
drugs.
Results
Our
findings,
with
SMR
results
showing
an
odds
ratio
(OR)
1.44
(95%
CI:
1.08–1.92;
P
=
0.011)
IVW-MR
indicating
OR
1.56
1.10–2.23;
0.013),
demonstrate
positive
correlation
PCSK9
increased
risk
CM.
However,
no
such
correlations
observed
other
analyses.
Conclusion
concludes
that
plays
significant
role
development
CM,
its
inhibition
reduced
disease.
Cancers,
Год журнала:
2023,
Номер
15(14), С. 3673 - 3673
Опубликована: Июль 19, 2023
Endometrial
cancer
(EC)
is
the
most
common
gynecologic
cancer.
The
overall
survival
remains
unsatisfying
due
to
lack
of
effective
treatment
screening
approaches.
Immunotherapy
as
a
promising
therapy
has
been
applied
for
EC
treatment,
but
still
fails
in
many
cases.
Therefore,
there
strong
need
optimize
approach
clinical
treatment.
In
this
study,
we
employed
co-expression
network
(GCN)
analysis
mine
immune-related
GCN
modules
and
key
genes
further
constructed
an
risk
score
model
(IRSM).
IRSM
was
proved
independent
predictor
poor
prognosis.
roles
IRSM-related
were
confirmed
by
IHC.
molecular
basis,
tumor
immune
microenvironment
characteristics
revealed.
Moreover,
effectiveness
associated
with
immunotherapy
chemotherapy.
Patients
low-risk
group
more
sensitive
chemotherapy
than
those
high-risk
group.
Interestingly,
patients
responding
also
Overall,
developed
which
could
be
used
predict
prognosis,
response
sensitivity
patients.
Our
not
only
improves
offers
targets
personalized
therapeutic
interventions.
Frontiers in Oncology,
Год журнала:
2024,
Номер
14
Опубликована: Июнь 21, 2024
The
relationship
between
blood
lipids,
lipid-modifying
medications,
and
cancer
risk
has
been
under
investigation
for
some
time.
Recent
studies
suggest
that
lipid-lowering
medications
might
influence
melanoma
outcomes,
though
findings
remain
controversial.
Our
study
aims
to
clarify
the
potential
causal
drugs
commonly
used
incidence
through
a
comprehensive
Mendelian
randomization
(MR)
analysis.
Frontiers in Immunology,
Год журнала:
2024,
Номер
15
Опубликована: Сен. 26, 2024
Melanoma,
recognized
as
one
of
the
most
immunogenic
malignancies
in
humans,
holds
paramount
significance
realm
immunotherapy.
However,
emergence
drug
resistance
and
occurrence
adverse
reactions
underscore
pressing
need
to
explore
increasingly
personalized
immunotherapeutic
modalities.
Extracellular
Vesicles
(EVs),
pivotal
derivatives
immune
cells,
assume
roles
by
encapsulating
proteins,
lipids,
nucleic
acids
within
bilayer
lipid
structures,
thereby
facilitating
targeted
delivery
other
cells.
This
orchestrated
process
orchestrates
critical
functions
including
antigen
presentation,
modulation,
induction
apoptosis
tumor
A
burgeoning
body
evidence
underscores
vast
therapeutic
potential
EVs
melanoma
treatment.
comprehensive
review
aims
delineate
derived
from
cells
such
dendritic
natural
killer
macrophages,
T
context
patients,
furnishing
invaluable
insights
for
future
direction
Pharmaceutics,
Год журнала:
2023,
Номер
15(10), С. 2377 - 2377
Опубликована: Сен. 23, 2023
Chemotherapy-induced
side
effects
restrain
anti-tumor
efficiency,
with
hyperlipidemia
being
the
most
common
accompanying
disease
to
cause
treatment
failure.
In
this
work,
a
chimeric
peptide-engineered
nanomedicine
(designated
as
PRS)
was
fabricated
for
synergistic
suppression
of
tumor
growth
and
therapy-induced
hyperlipidemia.
Within
nanomedicine,
matrix-targeting
peptide
palmitic-K(palmitic)CREKA
can
self-assemble
into
nano-micelle
encapsulate
Rapamycin
(mTOR
inhibitor)
SBC-115076
(PCSK9
inhibitor).
This
PRS
exhibits
uniform
nano-distribution
good
stability
which
enhances
intracellular
drug
delivery
tumor-targeting
delivery.
Also,
found
synergistically
inhibit
cell
proliferation
by
interrupting
mTOR
pathway
reducing
Rapamycin-induced
increasing
production
LDLR.
vitro
in
vivo
results
demonstrate
superiority
systematic
reduction
without
initiating
any
other
toxic
effects.
work
proposes
sophisticated
strategy
also
provides
new
insights
cooperative
management
chemotherapy-induced
Cancers,
Год журнала:
2023,
Номер
15(19), С. 4818 - 4818
Опубликована: Сен. 30, 2023
Using
an
LL2
cell-based
syngeneic
mouse
LC
model,
taxifolin
suppressed
allografts
along
with
the
appearance
of
578
differentially
expressed
genes
(DEGs).
These
DEGs
were
associated
enhancement
processes
related
to
extracellular
matrix
and
lymphocyte
chemotaxis
as
well
reduction
in
pathways
relevant
cell
proliferation.
From
these
DEGs,
we
formulated
12-gene
(TxflSig)
7-gene
(TxflSig1)
panels;
both
predicted
response
ICB
(immune
checkpoint
blockade)
therapy
more
effectively
non-small-cell
lung
cancer
(NSCLC)
than
numerous
well-established
biomarkers,
including
PD-L1.
In
panels,
counterparts
ITGAL,
ITGAX,
TMEM119
downregulated
by
taxifolin.
They
strongly
immune
suppression
LC,
evidenced
their
robust
correlations
major
immunosuppressive
types
(MDSC,
Treg,
macrophage)
multiple
checkpoints
NSCLC
across
human
types.
IIT
(ITGAL-ITGAX-TMEM119)
NSCLC’s
therapy;
stratified
mortality
risk
NSCLC.
The
stromal
expressions
ITGAL
together
tumor
expression
NSCLC,
demonstrated.
Collectively,
report
novel
biomarkers—TxflSig,
TxflSig1,
IIT,
ITGAX—and
taxifolin-derived
attenuation
activities
suggesting
inclusion
therapies
for
